ANALYTICAL QUALITY BY DESIGN (AQBD): CURRENT ADVANCES AND FUTURE PERSPECTIVES

Analytical methods play a vital role in pharmaceutical development, quality control, stability testing, and regulatory decision-making, as the reliability of drug product identity, strength, purity, safety, and stability depends on the quality of analytical data generated. Conventional analytical method development has traditionally followed trial-and-error and one-factor-at-a-time approaches, which can require extensive experimentation and may fail to adequately evaluate interactions among method variables. Analytical Quality by Design (AQbD) has emerged as a systematic, science-based, and risk-based approach for developing analytical procedures that are robust, reliable, and fit for their intended purpose. The AQbD framework generally begins with defining an Analytical Target Profile (ATP), followed by identification of critical analytical attributes and performance characteristics, risk assessment, identification of critical method parameters, application of Design of Experiments (DoE), establishment of a Method Operable Design Region (MODR), and development of an appropriate analytical control strategy. The recently finalized ICH Q14 guideline provides a harmonized framework for analytical procedure development and lifecycle management, while ICH Q2(R2) establishes an updated framework for analytical procedure validation. Together, these guidelines emphasize a science- and risk-based approach extending beyond validation as a standalone activity. Recent advances in AQbD include integration with multivariate analysis, chemometrics, automation, artificial intelligence, machine learning, green analytical chemistry, and real-time analytical technologies. This review discusses the fundamental concepts, workflow, statistical tools, applications, regulatory significance, advantages, challenges, and future perspectives of AQbD in pharmaceutical analysis. The integration of AQbD with digital and sustainable technologies is expected to enhance method robustness, reduce experimental burden, and support continuous analytical procedure improvement throughout the analytical lifecycle.

Authors

Publication Details

Journal
European Journal Pharmaceutical and Medical Research
Published
2026-10-01
DOI
https://doi.org/10.5281/zenodo.23031420
Primary Topic
Spectroscopy and Chemometric Analyses
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
article

ANALYTICAL QUALITY BY DESIGN (AQBD): CURRENT ADVANCES AND FUTURE PERSPECTIVES

Kowsalya Devi M., Karthiraja A. S.*, Dr. Saravanan V. S., Logesh P.
European Journal Pharmaceutical and Medical Research
Spectroscopy and Chemometric Analyses
article

ANALYTICAL QUALITY BY DESIGN (AQBD): CURRENT ADVANCES AND FUTURE PERSPECTIVES

Kowsalya Devi M., Karthiraja A. S.*, Dr. Saravanan V. S., Logesh P.
article en

Abstract

Analytical methods play a vital role in pharmaceutical development, quality control, stability testing, and regulatory decision-making, as the reliability of drug product identity, strength, purity, safety, and stability depends on the quality of analytical data generated. Conventional analytical method development has traditionally followed trial-and-error and one-factor-at-a-time approaches, which can require extensive experimentation and may fail to adequately evaluate interactions among method variables. Analytical Quality by Design (AQbD) has emerged as a systematic, science-based, and risk-based approach for developing analytical procedures that are robust, reliable, and fit for their intended purpose. The AQbD framework generally begins with defining an Analytical Target Profile (ATP), followed by identification of critical analytical attributes and performance characteristics, risk assessment, identification of critical method parameters, application of Design of Experiments (DoE), establishment of a Method Operable Design Region (MODR), and development of an appropriate analytical control strategy. The recently finalized ICH Q14 guideline provides a harmonized framework for analytical procedure development and lifecycle management, while ICH Q2(R2) establishes an updated framework for analytical procedure validation. Together, these guidelines emphasize a science- and risk-based approach extending beyond validation as a standalone activity. Recent advances in AQbD include integration with multivariate analysis, chemometrics, automation, artificial intelligence, machine learning, green analytical chemistry, and real-time analytical technologies. This review discusses the fundamental concepts, workflow, statistical tools, applications, regulatory significance, advantages, challenges, and future perspectives of AQbD in pharmaceutical analysis. The integration of AQbD with digital and sustainable technologies is expected to enhance method robustness, reduce experimental burden, and support continuous analytical procedure improvement throughout the analytical lifecycle.

European Journal Pharmaceutical and Medical Research
Openalex Percentile: Top 17%
Spectroscopy and Chemometric Analyses
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

ANALYTICAL QUALITY BY DESIGN (AQBD): CURRENT ADVANCES AND FUTURE PERSPECTIVES — Kowsalya Devi M., Karthiraja A. S.*, Dr. Saravanan V. S., Logesh P. · European Journal Pharmaceutical and Medical Research (2026) | TGRS Research Map | TGRS